2022
TCR gene segment usage and HLA alleles that are associated with cancer survival rates also represent racial disparities
Angelakakis G, Serraneau K, Barker V, Callahan B, Tong W, Zaman S, Huda T, Blanck G. TCR gene segment usage and HLA alleles that are associated with cancer survival rates also represent racial disparities. International Journal Of Immunogenetics 2022, 50: 41-47. PMID: 36585798, DOI: 10.1111/iji.12610.Peer-Reviewed Original ResearchConceptsTCR gene segment usageHLA allele combinationsGene segment usageCancer outcomesRacial disparitiesSegment usageHLA allelesCertain HLA allelesCancer survival ratesDistinct survival outcomesSocioeconomic factorsDisease courseSurvival outcomesInfectious disease courseSurvival rateAllele combinationsDifferent racial groupsGenetic polymorphismsPrevious pathogen exposurePathogen exposureOutcomesRacial groupsDisparitiesFactorsCancer
2020
TRBV and TRBJ usage, when paired with specific HLA alleles, associates with distinct head and neck cancer survival rates
Arndt MF, Koohestani DM, Chobrutskiy BI, Mihyu MM, Diaz M, Gozlan EC, Yeagley M, Zaman S, Roca AM, Blanck G. TRBV and TRBJ usage, when paired with specific HLA alleles, associates with distinct head and neck cancer survival rates. Human Immunology 2020, 81: 692-696. PMID: 32950267, DOI: 10.1016/j.humimm.2020.08.007.Peer-Reviewed Original ResearchMeSH KeywordsAllelesBiomarkers, TumorDisease-Free SurvivalExomeGenes, T-Cell Receptor betaHead and Neck NeoplasmsHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHLA AntigensHumansKaplan-Meier EstimatePrognosisReceptors, Antigen, T-Cell, alpha-betaSurvival RateV(D)J RecombinationConceptsHuman papilloma virusHLA allele combinationsT cell receptorSurvival rateCervical cancerHLA allelesParticular human leukocyte antigen (HLA) allelesBetter disease-free survival rateCancer Genome Atlas (TCGA) headDisease-free survival ratesJ usageHuman leukocyte antigen (HLA) allelesFree survival rateOverall survival rateCancer survival ratesSpecific HLA allelesDistinct overall survival ratesNeck cancer datasetPapilloma virusIndependent associationAntigen presentationAntigen allelesViral infectionHLAExome filesImmunogenomics of colorectal adenocarcinoma: Survival distinctions represented by immune receptor, CDR3 chemical features and high expression of BTN gene family members
Diaz MJ, Chobrutskiy BI, Zaman S, Blanck G. Immunogenomics of colorectal adenocarcinoma: Survival distinctions represented by immune receptor, CDR3 chemical features and high expression of BTN gene family members. Cancer Treatment And Research Communications 2020, 24: 100196. PMID: 32769037, DOI: 10.1016/j.ctarc.2020.100196.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAftercareAntineoplastic Agents, ImmunologicalBiomarkers, TumorButyrophilinsColorectal NeoplasmsComplementarity Determining RegionsComputational BiologyDisease-Free SurvivalExomeGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateReceptors, Antigen, B-CellReceptors, Antigen, T-CellRecombination, GeneticRNA-SeqSurvival RateConceptsSurvival rateLung cancerColon cancerImmune receptor recombinationsWorse survival rateCancer survival ratesCases of melanomaBetter survival rateB cell receptorFamily membersSurvival distinctionsCancer Genome AtlasImmunotherapy approachesColorectal adenocarcinomaT cellsImmunogenomics studiesCancer typesCancerConsistent associationHigh expressionGenome AtlasImmune receptorsImmunogenomic featuresMelanomaCancer exomes
2019
An age-based, RNA expression paradigm for survival biomarker identification for pediatric neuroblastoma and acute lymphoblastic leukemia
Diviney A, Chobrutskiy BI, Zaman S, Blanck G. An age-based, RNA expression paradigm for survival biomarker identification for pediatric neuroblastoma and acute lymphoblastic leukemia. Cancer Cell International 2019, 19: 73. PMID: 30962767, PMCID: PMC6438000, DOI: 10.1186/s12935-019-0790-5.Peer-Reviewed Original ResearchAcute lymphoblastic leukemiaOlder diagnostic ageDiagnostic agePediatric neuroblastomaLymphoblastic leukemiaPrevalent pediatric cancerCancer survival ratesAge of diagnosisYounger patientsSurvival differencesPediatric cancerHigh levelsPatientsNeuroblastomaSurvival rateGene expression markersAgeExpression markersLeukemiaSurvival metricsBiomarker identificationLevelsCancerDiseaseGenes